From our survey

FDA and ketamine myths St. Louis skeptics can set aside

Skepticism about ketamine therapy is healthy. Skepticism built on a wrong fact is not. In St. Louis, where ketamine clinics, telehealth services, and a certified esketamine site or two may all turn up in the same search, some of the most common doubts rest on misunderstandings about what the FDA has and has not approved.

This piece checks those beliefs. The goal is not to talk anyone into treatment. It is to make sure that if you say no, you are saying no to the right thing.

First, some context

Our summer poll, which we funded, heard from 443 adults living in Missouri, Illinois, and eight more Midwest states. Their gut response to ketamine therapy for depression or PTSD leaned wary: skeptical for 21 percent, negative for 9 percent, and cautious but open for the biggest group, 34 percent. FDA approval clearly carried weight, rated big or deciding by 59 percent of respondents.

These are whole-sample totals, and the skeptics' own view of FDA approval is not broken out here. All figures are final.

Myth: "There's no FDA-approved ketamine for depression."

There is one ketamine-based product approved for a form of depression. Spravato, a nasal spray form of esketamine, won FDA approval for treatment-resistant depression. What is true is that generic ketamine is approved only as an anesthetic, so IV ketamine for depression is off-label. Both statements can be accurate at once, which is exactly why this myth persists.

Very few people know the approved product exists. Of everyone we polled, 73 percent were hearing the name Spravato for the first time, and 6 percent could explain it.

Myth: "Spravato is basically street ketamine in a spray bottle."

It is a related molecule, but the comparison stops there. Esketamine is a pharmaceutical product made to FDA manufacturing standards, taken at a set dose, and given only at certified healthcare sites. You give yourself the spray while a clinician watches, remain on site for two hours or more, and skip driving until the following day. Nothing is sent home. Brain Recovery Centers outlines how a Spravato session is run for anyone who wants the specifics. Those safeguards exist precisely because the risks of misuse, sedation, and dissociation are taken seriously.

Myth: "Every ketamine clinic in St. Louis offers the FDA-approved version."

Not so. Many ketamine clinics offer IV infusions, which are an off-label use. Some telehealth services prescribe at-home ketamine, which is also off-label and sometimes compounded. Only certified sites can give Spravato. If FDA approval matters to you, ask a clinic which product it uses, and look the site up on the drugmaker's treatment center finder to confirm certification.

Myth: "If it's FDA-approved, it's risk-free."

Approval means benefits outweighed risks for the studied population, not that there are no risks. Esketamine's label names several, including sedation, dissociation, increased blood pressure, and potential for misuse. Some health conditions can rule it out. A skeptic is right to ask about risks even for an approved treatment, and a good clinician will answer plainly.

Myth: "Approval means it will work."

No depression treatment works for everyone. Approval reflects results across a group. Your own response cannot be predicted by a label, and anyone promising a result is overselling.

Myth: "FDA approval is just something drug companies buy."

Companies do pay for the trials, but they do not get to grade them. Manufacturers typically fund the clinical studies a drug needs, and they pay fees for review. The FDA then evaluates the evidence independently and can reject a drug, demand more data, or attach conditions. In esketamine's case, it attached a mandatory safety program that limits where and how the drug can be used. Skepticism about the pharmaceutical industry is understandable. The approval process is still a meaningful review that off-label and compounded products have not gone through for this use.

Myth: "Off-label means illegal."

Off-label prescribing is legal and common. A licensed prescriber may use an approved drug for another purpose. IV ketamine clinics operate legally. What off-label means is that the FDA has not reviewed that specific use. That is a reason to ask about the evidence, not proof of wrongdoing.

Myth: "Approved means insurance will pay for it."

Approval helps, but it does not ensure coverage. Most plans require prior authorization for esketamine, often with documentation of earlier medication trials. Coverage was the top priority our respondents named, picked by 85 percent when they could choose only two provider traits, far ahead of the 27 percent who chose FDA approval. If you are on MO HealthNet or an Illinois Medicaid plan, call and ask directly.

Myth: "If I'm skeptical of ketamine, my only other option is another pill."

There are drug-free paths. TMS relies on magnetic pulses from a scalp coil, not a medicine, and the FDA has cleared it for adult depression that antidepressants did not resolve. Psychotherapy is another. Nearly two thirds of our respondents, 64 percent, wanted a drug-free option to exist, yet just 25 percent could say what TMS is.

What skeptics can keep

Some doubts are well founded. It is reasonable to be wary of clinics that make vague FDA claims, promise results, or push prepaid packages. It is reasonable to ask about risks, dependence, and what happens if a treatment does not help. And it is reasonable, after hearing the facts, to decide that ketamine in any form is not for you.

Where to take the question

Take it to your own doctor. That recommendation is what would sway 74 percent of respondents, and more than half would begin at primary care. Whether any treatment suits you is a clinical judgment based on your history. Any current prescription should stay in place until you and its prescriber decide together to change it.

Myths can wait; a crisis cannot. If suicidal thoughts are present, 988 by text or call reaches the Suicide and Crisis Lifeline, free and private, in St. Louis and everywhere else, around the clock.

Methodology

The Pollfish consumer panel supplied respondents for survey 395586438, which stopped accepting answers June 23, 2026. There are 443 completes, adults 18 to 64 in Illinois, Missouri, Indiana, Kansas, Iowa, Ohio, Nebraska, Wisconsin, Oklahoma and Minnesota, and a consent screener preceded every one. The results are the final, validated ones. Our publisher commissioned the poll and paid for it.